Genzyme Europe, a biotechnology company, has selected SDL’s global information management system to meet the new regulatory translation management requirements in Europe, particularly the new XML-based product information management standard for the European Medicines Agency centralized procedure.
The SDL global information management system was selected by Genzyme to simplify regulatory processes through the deployment of a central translation management solution. The SDL system has the ability to support and enhance the process of creating multilingual content compliant with the upcoming EMEA XML-based product information management standard.
Raun Kupiec, director of regulatory affairs process management at Genzyme Europe, said: The SDL translation management software will allow us to optimize, automate and secure the current processes. This should help minimize the chance of errors and maximize our efficiency when having to manage our multiple language vendors. Comparison of versions and quality control is a very challenging task when dealing simultaneously with 23 languages on tight timelines.
Patrick Baudouin, vice-president of life sciences solutions at SDL, said: Genzyme is one of the industry leaders when it comes to the adoption of PIM, the new XML-based standard of the EMEA, and we are delighted that they have selected an SDL Global Information Management solution as a key element of their multilingual labeling platform. Genzyme clearly saw that even if they use external translation vendors, they will secure as many benefits from the implementation of the SDL solution as companies translating in-house.